Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer
Status:
Withdrawn
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial for women with newly diagnosed ovarian cancer. The purpose of this
study is to determine if the addition of a drug called azacitidine (Vidaza®)when added to
carboplatin and paclitaxel will change the genetic material of the tumor so that the
chemotherapy drugs work better.
The study will also determine what the maximum tolerated dose of azacitidine that may be
safely used in combination with carboplatin and paclitaxel.